- Home
- BLNK vs BMEA Comparison
BLNK vs BMEA Comparison
Compare BLNK & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- BMEA
- Stock Information
- Founded
- BLNK 2009
- BMEA 2017
- Country
- BLNK United States
- BMEA United States
- Employees
- BLNK N/A
- BMEA N/A
- Industry
- BLNK Industrial Specialties
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- BLNK Consumer Discretionary
- BMEA Health Care
- Exchange
- BLNK Nasdaq
- BMEA Nasdaq
- Market Cap
- BLNK 129.3M
- BMEA 125.0M
- IPO Year
- BLNK N/A
- BMEA 2021
- Fundamental
- Price
- BLNK $2.30
- BMEA $1.68
- Analyst Decision
- BLNK Buy
- BMEA Strong Buy
- Analyst Count
- BLNK 8
- BMEA 8
- Target Price
- BLNK $2.54
- BMEA $10.63
- AVG Volume (30 Days)
- BLNK 6.8M
- BMEA 2.7M
- Earning Date
- BLNK 11-06-2025
- BMEA 10-28-2025
- Dividend Yield
- BLNK N/A
- BMEA N/A
- EPS Growth
- BLNK N/A
- BMEA N/A
- EPS
- BLNK N/A
- BMEA N/A
- Revenue
- BLNK $104,788,000.00
- BMEA N/A
- Revenue This Year
- BLNK N/A
- BMEA N/A
- Revenue Next Year
- BLNK $19.30
- BMEA N/A
- P/E Ratio
- BLNK N/A
- BMEA N/A
- Revenue Growth
- BLNK N/A
- BMEA N/A
- 52 Week Low
- BLNK $0.63
- BMEA $1.29
- 52 Week High
- BLNK $2.65
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- BLNK 80.69
- BMEA 43.94
- Support Level
- BLNK $1.47
- BMEA $1.66
- Resistance Level
- BLNK $2.65
- BMEA $2.99
- Average True Range (ATR)
- BLNK 0.20
- BMEA 0.18
- MACD
- BLNK 0.09
- BMEA -0.02
- Stochastic Oscillator
- BLNK 96.78
- BMEA 10.75
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.